Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives.

Autor: Pecher AC; Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases and Department of Internal Medicine II, University Hospital Tuebingen, Otfried-Mueller-Strasse 10, 72076, Tuebingen, Germany., Henes M; Department of Obstetrics and Gynaecology, University Hospital Tuebingen, Tuebingen, Germany., Henes JC; Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases and Department of Internal Medicine II, University Hospital Tuebingen, Otfried-Mueller-Strasse 10, 72076, Tuebingen, Germany. Joerg.henes@med.uni-tuebingen.de.
Jazyk: angličtina
Zdroj: Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2023 Aug; Vol. 308 (2), pp. 379-385. Date of Electronic Publication: 2022 Sep 14.
DOI: 10.1007/s00404-022-06744-5
Abstrakt: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of systemic vasculitis characterized by autoantibodies against neutrophil cytoplasmic antigens (proteinase 3 PR3-ANCA and myeloperoxidase MPO-ANCA) and inflammation of small vessels. AAV include the diagnosis Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), which share many clinical and pathological features. Immunomodulatory therapies have significantly improved prognosis during the last decade. Nevertheless, especially in undiagnosed and thus uncontrolled AAV mortality due to renal impairment or pulmonary haemorrhages is still high. AAV are rare in fertile women, as the typical age of manifestation is above 50 years but there are women with AAV who are or want to become pregnant. This review focusses on how to manage patients with AAV planning to become pregnant and during their pregnancy.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: